These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 2239575)

  • 21. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.
    Rose PG; Blessing JA; Van Le L; Waggoner S
    Gynecol Oncol; 1998 Aug; 70(2):263-6. PubMed ID: 9740702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment for hormone-refractory or relapsing prostatic cancer].
    Hirao Y; Ozono S; Okajima E
    Gan To Kagaku Ryoho; 1996 Mar; 23(4):418-26. PubMed ID: 8678492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Alternating combination chemotherapy (VIP-DMF) in patients with advanced adenocarcinoma of the prostate].
    Yoshimoto J; Ochi J; Tanahashi T; Nanba K; Saegusa M; Hara M; Akagi T; Obama T; Tsushima T; Ozaki Y
    Gan To Kagaku Ryoho; 1987 Feb; 14(2):434-9. PubMed ID: 2434029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer.
    Harris KA; Weinberg V; Bok RA; Kakefuda M; Small EJ
    J Urol; 2002 Aug; 168(2):542-5. PubMed ID: 12131305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Histopathological effect of neoadjuvant chemohormonal therapy for prostatic cancer].
    Maruoka M; Hamano K; Nishikawa Y; Nagayama T
    Gan To Kagaku Ryoho; 1997 Oct; 24(13):1975-80. PubMed ID: 9350245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vinorelbine-based chemotherapy in hormone-refractory prostate cancer.
    Zampino MG; Verri E; Locatelli M; Curigliano G; Ascione G; Sbanotto A; Rocca A; Verweij F; Matei V; Scardino E; Decobelli O; Goldhirsch A; Nolè F
    Anticancer Res; 2006; 26(3B):2375-80. PubMed ID: 16821619
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer.
    Numata K; Miura N; Azuma K; Karashima T; Kasahara K; Nakatsuzi H; Hashine K; Sumiyoshi Y
    Hinyokika Kiyo; 2007 Feb; 53(2):99-104. PubMed ID: 17352158
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
    Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
    Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Weekly epidoxorubicin therapy in hormone-refractory metastatic prostate cancer.
    Neri B; Barbagli G; Bellesi P; Di Loro R; Lombardi V; Lombardo C; Magrini T; Mottola A; Nicita G; Palminteri E; Ponchietti R; Raugei A; Intini C
    Anticancer Res; 1997; 17(5B):3817-20. PubMed ID: 9427786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A phase II study of NK171 (etoposide)].
    Kimura K; Niitani H
    Gan To Kagaku Ryoho; 1985 Oct; 12(10):2011-7. PubMed ID: 2996442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Combination chemotherapy with FP versus FEP in patients with advanced gastric cancer. Research group of gastric cancer chemotherapy].
    Shinoda M; Morise K; Kusugami K; Iwase H; Ina K; Kaneko H; Horiuchi Y; Kuroiwa A; Suga S; Oka Y
    Gan To Kagaku Ryoho; 1995 Mar; 22(4):515-20. PubMed ID: 7887643
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.
    Hussain M; Tangen CM; Lara PN; Vaishampayan UN; Petrylak DP; Colevas AD; Sakr WA; Crawford ED;
    J Clin Oncol; 2005 Dec; 23(34):8724-9. PubMed ID: 16314632
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
    Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
    J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma.
    Solit DB; Morris M; Slovin S; Curley T; Schwartz L; Larson S; Kattan MW; Hartley-Asp B; Scher HI; Kelly WK
    Cancer; 2003 Nov; 98(9):1842-8. PubMed ID: 14584065
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carboplatin plus oral etoposide in elderly patients with advanced non small cell lung cancer. A phase II study.
    Gridelli C; Rossi A; Scognamiglio F; Guida C; Fiore F; Gatani T; Scoppa G; Pergola M
    Anticancer Res; 1997; 17(6D):4755-8. PubMed ID: 9494602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral etoposide in the treatment of hormone-refractory prostate cancer.
    Hussain MH; Pienta KJ; Redman BG; Cummings GD; Flaherty LE
    Cancer; 1994 Jul; 74(1):100-3. PubMed ID: 8004566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of melphalan, ICRF-159, and hydroxyurea in metastatic prostate cancer: a preliminary report.
    Kvols LK; Eagan RT; Myers RP
    Cancer Treat Rep; 1977; 61(2):311-2. PubMed ID: 326400
    [No Abstract]   [Full Text] [Related]  

  • 38. Methylglyoxal-bis(guanylhydrazone) in hormone-resistant adenocarcinoma of the prostate.
    Scher HI; Yagoda A; Ahmed T; Watson RC
    J Clin Oncol; 1985 Feb; 3(2):224-8. PubMed ID: 3968552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Melphalan in metastatic cancer of the prostate: a pilot study.
    Franks CR
    Cancer Treat Rep; 1979 Feb; 63(2):228-9. PubMed ID: 445500
    [No Abstract]   [Full Text] [Related]  

  • 40. Etoposide in prostatic cancer: experimental studies and phase II trial in patients with bidimensionally measurable disease.
    Scher HI; Sternberg C; Heston WD; Watson RC; Niedzwiecki D; Smart T; Hollander P; Yagoda A
    Cancer Chemother Pharmacol; 1986; 18(1):24-6. PubMed ID: 3757155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.